LRMR Stock Forecast & Price Target

Larimar Therapeutics has demonstrated significant progress with its lead product candidate, CTI-1601, as evidenced by a median increase in frataxin (FXN) expression from 2.7 pg/µg at baseline to 13.44 pg/µg after six months, surpassing levels observed in over 50% of healthy volunteers. Furthermore, the company reported a median improvement of -2.20 points in the modified Friedreich's Ataxia Rating Scale (mFARS), contrasted with a decline of +1.00 points in the FACOMS natural history population over the same period. These compelling clinical results highlight the potential effectiveness of CTI-1601, reinforcing a positive outlook for Larimar Therapeutics's stock.

The financial outlook for Larimar Therapeutics appears unfavorable due to a significant decrease in the FY29 revenue estimate, which has been reduced from $659 million to $407 million despite a projected 25% market share in the US Friedreich's ataxia (FA) market. Additionally, the median mFARS change reported at -2.20 points indicates a less favorable outcome relative to the FACOMS natural history population, which experienced a positive change of +1.00 point. This contrasting data suggests potential efficacy challenges for the company's lead product candidate, CTI-1601, which may impact investor confidence and future revenue generation.